"Teriparatide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
| Descriptor ID |
D019379
|
| MeSH Number(s) |
D06.472.699.590.850 D12.644.548.587.850
|
| Concept/Terms |
Teriparatide- Teriparatide
- hPTH (1-34)
- Human Parathyroid Hormone (1-34)
|
Below are MeSH descriptors whose meaning is more general than "Teriparatide".
Below are MeSH descriptors whose meaning is more specific than "Teriparatide".
This graph shows the total number of publications written about "Teriparatide" by people in this website by year, and whether "Teriparatide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Teriparatide" by people in Profiles.
-
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 06 16; 108(7):1787-1796.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Widespread disturbance in extracellular matrix collagen biomarker responses to teriparatide therapy in osteogenesis imperfecta. Bone. 2021 01; 142:115703.
-
Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy. J Bone Miner Res. 2018 02; 33(2):307-315.
-
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014 Feb; 124(2):491-8.
-
Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out. Endocr Pract. 2011 Nov-Dec; 17(6):957-9.
-
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun; 21(6):1041-5.
-
Defective coupling of apical PTH receptors to phospholipase C prevents internalization of the Na+-phosphate cotransporter NaPi-IIa in Nherf1-deficient mice. Am J Physiol Cell Physiol. 2007 Feb; 292(2):C927-34.
-
The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006 Jun 12; 166(11):1209-17.
-
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006 Mar; 21(3):354-65.